Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions

Benjamin T. Fitzgerald; Steven L. Cohn; Allan L. Klein

doi:10.3949/ccjm.72.Suppl_1.S24

Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions

Benjamin T. Fitzgerald, Steven L. Cohn, Allan L. Klein

Medicine

Research output: Contribution to journal › Article

3 Scopus citations

Abstract

Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.

Original language	English (US)
Pages (from-to)	s24-s30
Journal	Cleveland Clinic journal of medicine
Volume	72
Issue number	SUPPL.1
DOIs	https://doi.org/10.3949/ccjm.72.Suppl_1.S24
State	Published - Dec 1 2004

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.3949/ccjm.72.Suppl_1.S24

Fingerprint Dive into the research topics of 'Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions'. Together they form a unique fingerprint.

Cite this

Fitzgerald, B. T., Cohn, S. L., & Klein, A. L. (2004). Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions. Cleveland Clinic journal of medicine, 72(SUPPL.1), s24-s30. https://doi.org/10.3949/ccjm.72.Suppl_1.S24

@article{b71fdf7dc85441c0b6c8c95b463969a3,

title = "Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions",

abstract = "Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.",

author = "Fitzgerald, {Benjamin T.} and Cohn, {Steven L.} and Klein, {Allan L.}",

year = "2004",

month = dec,

day = "1",

doi = "10.3949/ccjm.72.Suppl_1.S24",

language = "English (US)",

volume = "72",

pages = "s24--s30",

journal = "Cleveland Clinic Journal of Medicine",

issn = "0891-1150",

publisher = "Cleveland Clinic Educational Foundation",

number = "SUPPL.1",

}

TY - JOUR

T1 - Stroke prevention in atrial fibrillation

T2 - Current anticoagulation management and future directions

AU - Fitzgerald, Benjamin T.

AU - Cohn, Steven L.

AU - Klein, Allan L.

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.

AB - Atrial fibrillation (AF) is an important cause of stroke, and stroke risk stratification is critical to the management of patients with AF. Anticoagulation with warfarin is the current standard of care for stroke prevention in these patients, despite the need for close monitoring. Aspirin alone is not as effective. Warfarin is recommended for patients with AF and valvular disease or with AF and one or more stroke risk factors. Other novel anticoagulants and antiplatelet combinations are under investigation. Curative procedures for AF are possible, but their long-term safety and effect on stroke risk are unknown.

UR - http://www.scopus.com/inward/record.url?scp=84884549179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884549179&partnerID=8YFLogxK

U2 - 10.3949/ccjm.72.Suppl_1.S24

DO - 10.3949/ccjm.72.Suppl_1.S24

M3 - Article

AN - SCOPUS:84884549179

VL - 72

SP - s24-s30

JO - Cleveland Clinic Journal of Medicine

JF - Cleveland Clinic Journal of Medicine

SN - 0891-1150

IS - SUPPL.1

ER -